CCHT(SZ:000661) Xin Lang Cai Jing·2025-09-08 10:00Core Viewpoint - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the clinical trial application of GS3-007a, an orally administered small molecule growth hormone secretagogue, aimed at treating pediatric growth hormone deficiency (PGHD) [1] Group 1 - The clinical trial application for GS3-007a has been accepted, which is a significant step in the product's clinical development [1] - GS3-007a is classified as a Class 1 chemical drug and is intended for the treatment of children with growth retardation due to endogenous growth hormone deficiency [1] - Currently, there are no similar products available in the domestic market, indicating a potential unmet clinical need [1]